Abstract 2099: Model-driven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Communication Dans Un Congrès Année : 2016
Fichier non déposé

Dates et versions

hal-01404637 , version 1 (29-11-2016)

Identifiants

Citer

Joseph Ciccolini, Sebastien Benzekry, Sarah Giacometti, Fabrice Barlesi, Dominique Barbolosi. Abstract 2099: Model-driven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice. 107th Annual Meeting of the American Association for Cancer Research, 2016, New Orleans, France. pp.20, ⟨10.1158/1538-7445.AM2016-2099⟩. ⟨hal-01404637⟩
150 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More